MedTrace Logo

Efficacy and Safety of COVID-19 Convalescent Plasma

NCT04397523 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-05-28

Study results available
· View outcomes & findings →

Summary

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Conditions

  • Convalescent Plasma
  • COVID-19
  • SARS-CoV 2

Interventions

BIOLOGICAL

anti-SARS-CoV-2 convalescent plasma

Administration of convalescent plasma obtained from donors with prior documented SARS-CoV-2 infection

Sponsors & Collaborators

  • University Clinic for Infectious Diseases, North Macedonia

    collaborator OTHER

  • Institute for Transfusion Medicine of RNM

    lead OTHER_GOV

Principal Investigators

  • Rada Grubovic Rastvorceva, MD MSci PhD · Institute for Transfusion Medicine of RNM

  • Sedulla Useini, MD · Institute for Transfusion Medicine of RNM

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2021-05-10
Completion
2021-05-10

Countries

  • North Macedonia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04397523 on ClinicalTrials.gov